RxDoctor Payments Data

Sofia Horvath, MD

Cardiovascular Disease · Hialeah, FLNPI 1619366259

Payments from drug & device makers

$9,653in general payments, 2019–2025

Across 353 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Abbott$2K
  • Novartis$932
  • Pfizer$554
  • Amgen$550
  • Boston Scientific$497
  • plus $4K from 34 others

What the payments were for

  • Travel & lodging$2,18123%
  • Food & beverage$7,45877%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,653 in reported general payments places this provider in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$59,908
Medicare patients
379
Services billed
833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis51$1,164,107
EliquisApixaban332$295,414
EntrestoSacubitril/Valsartan225$196,978
Repatha SureclickEvolocumab157$156,446
XareltoRivaroxaban154$135,403
FarxigaDapagliflozin Propanediol122$93,738
CamzyosMavacamten12$86,806
VascepaIcosapent Ethyl126$55,903
OzempicSemaglutide36$34,235
JardianceEmpagliflozin24$26,101
MultaqDronedarone Hcl20$23,492
BrilintaTicagrelor30$15,904
Praluent PenAlirocumab19$13,692
Ranolazine ErRanolazine46$3,729
Metoprolol Succinate417$3,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$554$1,459,521383 claims
NovartisEntresto$932$196,978225 claims
Johnson & JohnsonXarelto$341$135,403154 claims
AstraZenecaFarxiga, Brilinta$344$109,642152 claims
E.r. Squibb & Sons, L.L.C.Camzyos$437$86,80612 claims
Novo NordiskOzempic$184$34,23536 claims
Boehringer IngelheimJardiance$18$26,10124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →